OncoInsight
LIVE CELL FOR PATIENT LIFE
Allogeneic Natural Killer Cells Engineered to Solid tumor
Natural killer cells can be xenografted and have the potential to become off-the-shelf products, making CAR-NK cell therapies universal products. These products are safer than CAR-T cell therapy.
iPSC derived Mesenchymal stem cells with Immunomodulatory ability
iPSC-derived MSCs express typical MSC immunophenotype, and seek to develop products as potential sources of unlimited, standardized, high‐quality cells for therapeutic applications in immune disease.
Humanized Mice as Unique Tools for Human-Specific Studies
Humanized mice support the development of multiple cellular components of the human immune system, many of which are functional and used in modeling key portions of human immunity.
OUR VISION
To be the leading company delivering innovative,
accessible cell therapies for cancer patients
OUR MISSION
We strive to discover, develop and deliver novel
off-the-shelf NK cell therapy product candidates
that have a profound impact on cancer patients
LEADERSHIP
Deukchae Na, Ph.D.
CHIEF EXECUTIVE OFFICER
Miyeon Lee, MOT
CHIEF OPERATING OFFICER
SCIENTIFIC ADVISORY BOARD
Junwoo Lee, M.D.
- 01
- 02
SCIENCE
CAR NK cell therapy
CAR NK cell therapy involves the infusion of NK cells that have been genetically engineered to express a chimeric antigen receptor (CAR) to reprogram the NK cells. The CAR combines the specificity of a monoclonal antibody with the cytotoxic and memory functions of NK cells.
CAR NK Cell Expansion and Persistence
CAR NK cells are expanded, or grown, outside the body to an appropriate therapeutic dose. Some studies have also reported
a correlation between CAR NK cell dose and the incidence
The impact of CAR NK cell dose on safety outcomes is unknown and may differ between products and disease states.
How CAR NK Cell Therapy Is Thought to Work
While the mechanism of action is not fully understood, evidence suggests that CAR NK cell therapies stimulate a T cell response against antigen-expressing cells, including normal and malignant cells.
The external targeting domain binds to the antigen, activating the CAR NK cell.
PIPELINE
BOARD
ARTICLE
RECRUITMENT
CONTACT US
+82-2-2088-3455
oncoinsight_biz@oncoinsight.co.kr
5th and 6th Floors, R&D Block, Omnibus Park,
oncoinsight_biz@oncoinsight.co.kr
5th and 6th Floors, R&D Block, Omnibus Park,
222 Banpo-daero, Seocho-gu, Seoul
06591, South Korea